Accent Therapeutics, a clinical-stage biopharmaceutical company pioneering novel small molecule precision cancer therapies, ...

Neoadjuvant chemoimmunotherapy demonstrated high pathological response rates with “manageable” toxicity in patients with squamous cell lung cancer, according to data presented at European Lung Cancer ...

New ELCC 2026 data show longer survival, better brain metastases control and more personalized treatment options for patients ...

Dr. Brian S. Henick, a medical oncologist at Columbia University Irving Medical Center and director of the phase 1 program and translational research in aerodigestive cancers, outlined in an interview ...

We read with interest the results of the HARMONi-6 trial by Zhiwei Chen and colleagues,1 which showed that ivonescimab plus chemotherapy improved progression-free survival versus tislelizumab plus ...

Screening individuals for lung cancer with low-dose CT on a nonrisk basis is associated with a marked reduction in lung cancer mortality and better overall survival, reveals Chinese data.

CHAF1B, a histone chaperone component of the chromatin assembly factor-1 complex, is overexpressed in multiple cancers and linked to tumor progression, but its role in lung squamous-cell carcinoma ...

Lung Squamous cell carcinoma (LSCC) represents the second most common non-small cell lung cancer. Although studies identified adenocarcinoma-like driver mutations in LSCC using next-generation ...